Therapeutic interventions for Burkitt's lymphoma in children

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Okebe, Joseph U ^a   Lasserson, T J ^b   Meremikwu, M M ^b   Richards, S ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DATA ANALYSIS; HUMAN; INFORMATION PROCESSING; METHODOLOGY; MONOTHERAPY; QUALITY CONTROL; REVIEW; SURVIVAL; SYSTEMATIC REVIEW;

EID: 42749107485     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005198.pub2     Document Type: Review

References (54)

1. Anderson JR, Wilson JF, Jenkin DT, Meadows AT, Kersey J, Chilcote RR, et al. Childhood non-Hodgkin's lymphoma. The results of a randomised therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). The New England journal of medicine 1983;308(10):559-65.
2. Brecher ML, Schwenn MR, Coppes MJ, Bowman WP, Link MP, Berard CW, et al. Fractionated cyclophosphamide and back to back high dose methrotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small non-cleaved cell lymphomas (snccl): a randomised trial of the pediatric oncology group. Medical and Pediatric oncology 1997;29(6):526-33.
3. Cairo M.S, Gerrard M, Sposto R, Auperin A, Pinkerton R, Michon J, et al. Results of a randomised FAB LMB89 international study in children and adolescents (C+A) with advanced (bone marrow [BM] [B-ALL] and/or CNS) B-NHL (large cell [LCL], Burkitt's [BM] and Burkitt-like [BLL]): Pts with L3 leukemia/ CNS- have an excellent prognosis. Procdeedings of the American society of Clinical Oncology. 2003; Vol. 22:796.
4. Magrath IT, Ziegler. Prophylaxis of meningeal Burkitt's lymphoma with CCNU. American association for cancer research 1973;14:67.
5. * Magrath IT, Ziegler JL. Failure of BCG immunostimulation to affect the clinical course of Burkitt's Lymphoma. British Medical Journal 1976;1:615-8.
6. Magrath IT, Ziegler JL, Bluming AZ. Preliminary results of a randomized trial of BCG immunotherapy in Burkitt's lymphoma. Recent results in cancer research 1974;47:461-5.
7. Ziegler JL, Magrath IT. BCG immunotherapy in Burkitt's lymphoma: preliminary results of a randomized clinical trial. National cancer institute monograph 1973;39:199-202.
8. Ziegler JL, Magrath IT, Bluming AZ. BCG immunotherapy of Burkitt's lymphoma. Proceedings of the American association for cancer research. 1972; Vol. 13:38.
9. Neequaye J, Viza D, Pizza G, Levine P, De Vinci C, Ablashi D, Biggar R, Nkrumah F. Specific transfer factor with activity against Ebstein-Barr virus reduces late relapse in endemic Burkitt's lymphoma. Anticancer research 1990;10(5A):1183-7.
10. Olweny CLM, katongole-Mbide E, Kaddu-Mukassa A, Atine I, et al. Treatment of Burkitt's lymphoma: randomized clinical trial of single-agent versus combination chemotherapy. Journal International du cancer 1976;17(4):436-40.
11. Olweny CLM, Atine I, Kaddu-Mukassa A, katongole-Mbide E, Lwanda SK, Johansson B, et al. Cerebrospinal irradiation of Burkitt's lymphoma. Acta radiologica: therapy, physics, biology 1977;16(3):225-31.
12. Patte C, Philip T, Rodary C, Zucker J, Behrendt H, Gentet J, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French pediatric oncology society of a randomized trial of 216 children. Journal of clinical oncology 1991;9(1):123-32.
13. Sullivan MP, Brecher M, Ramirez I, Ragab A, Hvizdala E, Pullen J, et al. High-dose Cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a pediatric oncology group study. The American journal of pediatric hematology /oncology 1991;13(3):288-95.
14. Ziegler JL, Bluming AZ. Intrathecal chemotherapy in Burkitt's lymphoma. British medical journal 1971;3(773):508-12.
15. Ziegler JL, Bluming AZ, Magrath IT, Carbone PP. Intensive chemotherapy in patients with generalized Burkitt's lymphoma. International journal of cancer 1972;10(2):254-61.
16. Adde M, Shad A, Venzon D, Arndt C, Gootenberg J, Neely J, et al. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Seminars in oncology 1998;25(2 suppl 4):33-9.
17. Aviles A, Delgado S, Huerta-Guzman J. Marginal zone B cell lymphoma of the parotid glands. European journal of cancer part B, oral oncology 1996;32B(6):420-2.
18. Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon P A. et al. For the GELA group (Groupe d'Etude des lymphomas Aggressives). Peripheral T-cell lymphocytes have a poorer prgnosis thab B-cell lympomas: A prospective study of 361 immunotyped patients treated with LNH-84 regimen. Journal of the European society for medical oncology/ESMO 1990;1(1):45-50.
19. Gururagan S, Sposto R, Cairo MS, Meadows A T, Finlay J L. Outcome of CNS disease at diagnosis in disseminated small non-cleaved cell lymphoma and B-cell leukaemia: a children's cancer group study. Journal of clinical oncology 2000;18(10):2017-25.
20. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco AF. Maximising therapeutic effect of rituximab: maintenance treatment vs. re-treatment at progression in patients with indolent non-Hodgkin's lymphoma- a randomized phase two trial of the Minie Pearl research network. Journal of clinical oncology 2005;23(6):1088-95.
21. Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H, et al. Comparison of autologous bone marrow transplantation (BMT) with sequential chemotherapy for aggressive non-Hodgkin's lymphoma in first remission: a study on 464 patients (LNH 87 protocol). 5th international conference on malignant lymphoma. 1993: 85a.
22. Hsu FJ, Casper CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma- long term results of a clinical trial. Blood 1997;89(9):3129-35.
23. Kaplan LD, Kahn JO, Crawe S, Northfelt D, Neville P, Grossberg H, et al. Clinical and virologic effects of recombinant human-granulocyte colony stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. Journal of clinical oncology 1991;9(6):929-40.
24. Kimby E, Mellstedt H. Chlorambucil/prednisolone (CHP) versus CHOP in symptomatic low grade lymphomas. 5th international conference on malignant lymphoma. 1993.
25. Levine AM, Wernz JC, Kaplan L, Rodman N, Cohen P, Metroka C, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS- related lymphoma. JAMA 1991;266(1):84-8.
26. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenburg J, Grillo-lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric Anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84(8):2457-66.
27. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. Journal of clinical oncology 1997;15(10):3266-74.
28. Olweny CLM, Ziegler JL. Treatment of histiocytic lymphoma in Ugandan adults. East African medical journal 1971;48(10):585-91.
29. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSNHL. Blood 2004;104(3):626-33.
30. Reiter A, Tiemann M, Ludwig WD, Wacker HH, Yakisan E, Schrappe M, et al. NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 1: classification and allocation to strategic therapy groups. BIF study group [Therapiestudie NHL-BFM 90 zyr behandlung maligner non-Hodgkin-lymphome bei kindern und jugendlichen. tiel 1: klassifikation und einteilung in stategische therapiegruppen]. Klinische padiatrie 1994;206(4):222-33.
31. Reiter A, Schrappe M, Yakistan E, Sauter S, Ebell W, Zimmermann M, et al. NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: an intermediate term analysis of the B-NHL/B-ALL [Therapiestudie NHL-BFM 90 zur behandlung maligner non-Hodkin-lymphome bei kindern und jugendlichen. Teil 3: eine zwischenanalyse der therapiegruppe B-NHL/B-ALL]. Klinische padiatrie 1994;204(4): 242-52.
32. Tilly H, Mounier N, Lederlin P, Dupriez B, Sebban C, Bosly A, et al. Randomized comparison of ACVBP and m-BACOD in the treatment o patients with low-risk aggressive lymphoma: the LNH87-1 study. Journal of clinical oncology 2000;18(6):1309-15.
33. Tura S, Mandelli F, Mazza P, Pileri S, Gherlinzoni F, Bocchia M, et al. MACOP-B vs. MACHOP in the treatment of high-grade non-Hodgkin's lymphoma. Leukemia 1991;5((suppl 1)):74-8.
34. Witzig TE. The use of Ibritumomab tiuxetan radioimmunology for patients with relapsed B-cell non-Hodgkin's lymphoma. Seminars in oncology 2000;27((suppl 12)):74-8.
35. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of Yttrium-90-labeled Ibritumomab Tiuxetan radioimmunotherapy versus Rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of clinicaloncology 2002;20(10):2453-63.
36. Burkitt DP. Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer 1967;20(5):756-9.
37. White L, Siegel SE, Quah TC. PNon-hodgkin's lymphomas in chilgren. II. treatmentrognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma. Clinical reviews in oncology/hematology 1992;13(1):73-89.
38. Bernheim A, Berger R, Lenoi G. Cytogenic studies on African Burkitt's lymphoma cell lines; t(8;14),t(2;8), and t(8;22) translocations. Cancer Genetics and Cytogenetics 1981;3:307-15.
39. Burkitt. Sarcoma involving jaws in African children. British journal of surgery 1958;46:218-23.
40. Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, Anderson JR, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. British Journal of Haematology 2003;4:660-70.
41. Goldstein J A, Berstein R L. Burkitt's lymphoma and the role of Ebstein- Barr virus. Journal of tropical paediatrics 1990;30:114-9.
42. Magrath IT, Ziegler JL, Bluming AZ. Preliminary results of a randomized trial of BCG immunotherapy in Burkitt's lymphoma. Recent results in cancer research 1974;47:461-5..
43. Magrath I T, Lwanga S, Carswell W, Harrison N. Surgical reduction of tumor bulk in management of abdominal Burkitt's Lymphoma. British Medical Journal 1974;2:308-12.
44. Magrath IT. Malignant non-Hodgkin's lymphomas in children. Hematology and oncology Clinics of North America 1987;1(4):577-602.
45. Magrath IT, Shiramizu B. Biology and treatment of small non-cleaved cell lymphoma. Biology and treatment of small non-cleaved cell lymphoma. Biology and treatment of small non-cleaved cell lymphoma. Oncology 1989;3(11):41-53.
46. Meremikwu MM, Ehiri JE, Nkanga DG, Udoh EE, Ikpatt OF, Alaje EO. Socio-economic constraints to effective management of Burkitt's lymphoma in south-east Nigeria. Tropical medicine and international health 2005 (in press).
47. Norlin T, Clifford P, Einhorn J, et al. Conventional and superfractionated radiation therapy in Burkit's lymphoma. Acta Radiologica 1971;10:545-57.
48. Oguonu T, Emodi I, Kaine W. Epidemiology of Burkitt's lymphoma in Enugu, Nigeria. Annals of tropical paediatrics 2002;22(4):369-74.
49. Olweny CL, Katongole-Mbidde E, Otim D, Lwanga SK, Magrath IT, Ziegler JL. Long-term experience with Burkitt's lymphoma in Uganda. International journal of cancer 1980;26(3):261-6.
50. Smeland S, Blystad AK, Kvaloy SO, Ikonomou IM, Delabie J, Kvalheim G, et al. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Annals of Oncology 2004;15(7):1072-78.
51. Sugimoto M, Tahara H, Ide T, Furuichi Y. Steps involed in immortalization and tumorigenesis of human b-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer research 2004;64(10):3361-4.
52. Ziegler J L. Chemotherapy of Burkitt's lymphoma. Cancer 1972;30:1534-40.
53. Ziegler J L, Magrath I T. Pathology annual. Ioachim H L. New York: Apleton-Century-Crofts, 1974.
54. Ziegler JL. Burkitt's Lymphoma. New England Journal of Medicine 1981;305:735-45.